Does the media refer more to ASND or RLAY?

In the previous week, Ascendis Pharma A/S had 19 more articles in the media than Relay Therapeutics. MarketBeat recorded 30 mentions for Ascendis Pharma A/S and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.22 beat Ascendis Pharma A/S's score of 0.41 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 9 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Relay Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BBIO or RLAY?

In the previous week, BridgeBio Pharma had 16 more articles in the media than Relay Therapeutics. MarketBeat recorded 27 mentions for BridgeBio Pharma and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.22 beat BridgeBio Pharma's score of 0.37 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 9 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Relay Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, EXEL or RLAY?

Exelixis has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.30 $782.57M $3.18 18.56 Relay Therapeutics $15.35M 271.82 -$276.48M -$1.57 N/A

Does the media prefer EXEL or RLAY?

In the previous week, Exelixis had 12 more articles in the media than Relay Therapeutics. MarketBeat recorded 23 mentions for Exelixis and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.22 beat Exelixis' score of 0.81 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RLAY or BMRN?

In the previous week, BioMarin Pharmaceutical had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 13 mentions for BioMarin Pharmaceutical and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.22 beat BioMarin Pharmaceutical's score of 0.73 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 5 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RLAY or MDGL?

In the previous week, Relay Therapeutics had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 11 mentions for Relay Therapeutics and 6 mentions for Madrigal Pharmaceuticals. Relay Therapeutics' average media sentiment score of 1.22 beat Madrigal Pharmaceuticals' score of 1.07 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Relay Therapeutics (RLAY) Competitors

$19.04 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

RLAY vs. ASND, BBIO, EXEL, BMRN, and MDGL

Should you buy Relay Therapeutics stock or one of its competitors? Relay Therapeutics's main competitors and comparable companies include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Relay Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Ascendis Pharma A/S presently has a consensus price target of $310.05, suggesting a potential upside of 14.60%. Relay Therapeutics has a consensus price target of $25.92, suggesting a potential upside of 36.12%. Given Relay Therapeutics' higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Ascendis Pharma A/S has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.72	-$258M	$12.89	20.99
Relay Therapeutics	$15.35M	271.82	-$276.48M	-$1.57	N/A

97.0% of Relay Therapeutics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Ascendis Pharma A/S had 19 more articles in the media than Relay Therapeutics. MarketBeat recorded 30 mentions for Ascendis Pharma A/S and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.22 beat Ascendis Pharma A/S's score of 0.41 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	9 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relay Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 70.99% compared to Relay Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Relay Therapeutics	N/A	-42.27%	-38.67%

Ascendis Pharma A/S has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

Summary

Ascendis Pharma A/S beats Relay Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Relay Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Relay Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	29.14	-$724.93M	-$3.57	N/A
Relay Therapeutics	$15.35M	271.82	-$276.48M	-$1.57	N/A

BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

In the previous week, BridgeBio Pharma had 16 more articles in the media than Relay Therapeutics. MarketBeat recorded 27 mentions for BridgeBio Pharma and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.22 beat BridgeBio Pharma's score of 0.37 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	9 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relay Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Relay Therapeutics	N/A	-42.27%	-38.67%

BridgeBio Pharma presently has a consensus target price of $101.53, indicating a potential upside of 35.66%. Relay Therapeutics has a consensus target price of $25.92, indicating a potential upside of 36.12%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Relay Therapeutics beats BridgeBio Pharma on 11 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Exelixis had 12 more articles in the media than Relay Therapeutics. MarketBeat recorded 23 mentions for Exelixis and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.22 beat Exelixis' score of 0.81 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.3% of Exelixis shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Exelixis currently has a consensus target price of $50.07, suggesting a potential downside of 15.16%. Relay Therapeutics has a consensus target price of $25.92, suggesting a potential upside of 36.12%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Exelixis has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market.

Exelixis has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.30	$782.57M	$3.18	18.56
Relay Therapeutics	$15.35M	271.82	-$276.48M	-$1.57	N/A

Exelixis has a net margin of 35.33% compared to Relay Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Relay Therapeutics	N/A	-42.27%	-38.67%

Summary

Relay Therapeutics beats Exelixis on 9 of the 17 factors compared between the two stocks.

How does Relay Therapeutics compare to BioMarin Pharmaceutical?

Relay Therapeutics (NASDAQ:RLAY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

BioMarin Pharmaceutical has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	271.82	-$276.48M	-$1.57	N/A
BioMarin Pharmaceutical	$3.22B	4.00	$348.90M	$0.37	179.81

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Relay Therapeutics currently has a consensus price target of $25.92, suggesting a potential upside of 36.12%. BioMarin Pharmaceutical has a consensus price target of $89.17, suggesting a potential upside of 34.04%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.74

In the previous week, BioMarin Pharmaceutical had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 13 mentions for BioMarin Pharmaceutical and 11 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.22 beat BioMarin Pharmaceutical's score of 0.73 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	5 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relay Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Relay Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Summary

BioMarin Pharmaceutical beats Relay Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Relay Therapeutics compare to Madrigal Pharmaceuticals?

Relay Therapeutics (NASDAQ:RLAY) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Relay Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	271.82	-$276.48M	-$1.57	N/A
Madrigal Pharmaceuticals	$958.40M	13.04	-$288.28M	-$12.89	N/A

In the previous week, Relay Therapeutics had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 11 mentions for Relay Therapeutics and 6 mentions for Madrigal Pharmaceuticals. Relay Therapeutics' average media sentiment score of 1.22 beat Madrigal Pharmaceuticals' score of 1.07 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 5.0% of Relay Therapeutics shares are held by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Relay Therapeutics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market.

Relay Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Relay Therapeutics' return on equity of -42.27% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Relay Therapeutics currently has a consensus price target of $25.92, indicating a potential upside of 36.12%. Madrigal Pharmaceuticals has a consensus price target of $699.64, indicating a potential upside of 29.30%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Relay Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Relay Therapeutics beats Madrigal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get Relay Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLAY vs. The Competition

Export

Metric	Relay Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.17B	$4.01B	$7.25B	$12.91B
Dividend Yield	N/A	3.60%	2.54%	9.13%
P/E Ratio	-12.13	12.65	273.27	25.43
Price / Sales	271.82	1,344.31	624.55	95.06
Price / Cash	N/A	45.00	28.92	35.62
Price / Book	5.82	16.39	11.01	6.39
Net Income	-$276.48M	-$22.85M	$3.49B	$358.69M
7 Day Performance	3.59%	1.43%	1.63%	0.22%
1 Month Performance	-3.69%	6.00%	4.42%	-0.10%
1 Year Performance	362.14%	49.38%	24.21%	14.04%

Relay Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLAY Relay Therapeutics	2.7672 of 5 stars	$19.04 flat	$25.92 +36.1%	+362.1%	$4.17B	$15.35M	N/A	330	Positive News
ASND Ascendis Pharma A/S	4.2481 of 5 stars	$263.04 +6.1%	$304.95 +15.9%	+31.4%	$15.46B	$814.57M	20.41	1,189	Positive News Gap Down High Trading Volume
BBIO BridgeBio Pharma	3.1412 of 5 stars	$76.59 0.0%	$100.79 +31.6%	+40.2%	$14.97B	$502.08M	N/A	400	Analyst Revision
EXEL Exelixis	2.8942 of 5 stars	$54.64 +0.3%	$50.07 -8.4%	+55.8%	$13.49B	$2.32B	17.18	1,077	Positive News Analyst Revision
BMRN BioMarin Pharmaceutical	4.8571 of 5 stars	$65.23 +0.9%	$88.92 +36.3%	+15.2%	$12.52B	$3.22B	176.30	3,221

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLAY) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relay Therapeutics (RLAY) Competitors

RLAY vs. ASND, BBIO, EXEL, BMRN, and MDGL

How does Relay Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Relay Therapeutics compare to BridgeBio Pharma?

Summary

How does Relay Therapeutics compare to Exelixis?

Summary

How does Relay Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Relay Therapeutics compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relay Therapeutics (RLAY) Competitors

RLAY vs. ASND, BBIO, EXEL, BMRN, and MDGL

How does Relay Therapeutics compare to Ascendis Pharma A/S?

Do analysts recommend ASND or RLAY?

Which has stronger valuation & earnings, ASND or RLAY?

Do institutionals & insiders hold more shares of ASND or RLAY?

Does the media refer more to ASND or RLAY?

Is ASND or RLAY more profitable?

Which has more risk and volatility, ASND or RLAY?

Summary

How does Relay Therapeutics compare to BridgeBio Pharma?

Which has better valuation & earnings, BBIO or RLAY?

Which has more risk and volatility, BBIO or RLAY?

Does the media favor BBIO or RLAY?

Is BBIO or RLAY more profitable?

Do analysts recommend BBIO or RLAY?

Do institutionals & insiders believe in BBIO or RLAY?

Summary

How does Relay Therapeutics compare to Exelixis?

Does the media prefer EXEL or RLAY?

Do institutionals and insiders hold more shares of EXEL or RLAY?

Do analysts rate EXEL or RLAY?

Which has more volatility & risk, EXEL or RLAY?

Which has stronger valuation and earnings, EXEL or RLAY?

Is EXEL or RLAY more profitable?

Summary

How does Relay Therapeutics compare to BioMarin Pharmaceutical?

Which has preferable valuation and earnings, RLAY or BMRN?

Do insiders and institutionals hold more shares of RLAY or BMRN?

Do analysts recommend RLAY or BMRN?

Does the media prefer RLAY or BMRN?

Which has more risk and volatility, RLAY or BMRN?

Is RLAY or BMRN more profitable?

Summary

How does Relay Therapeutics compare to Madrigal Pharmaceuticals?

Which has higher valuation & earnings, RLAY or MDGL?

Does the media favor RLAY or MDGL?

Do institutionals and insiders hold more shares of RLAY or MDGL?

Which has more risk & volatility, RLAY or MDGL?

Is RLAY or MDGL more profitable?

Do analysts recommend RLAY or MDGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY vs. The Competition

Relay Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools